MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-14-2024
Acorda Therapeutics Revenue 2011-2026 | ACOR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118 M | 119 M | 129 M | 153 M | 192 M | 471 M | 588 M | 520 M | 493 M | 401 M | 336 M | 306 M | 292 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 588 M | 118 M | 317 M |
Quarterly Revenue Acorda Therapeutics
| 2024-Q1 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.3 M | 22.3 M | - | 33.5 M | 31.1 M | 22.5 M | - | 31.5 M | 31.8 M | 28.9 M | - | 53.1 M | 33.6 M | 28.1 M | 50.5 M | 47.7 M | 50.1 M | 44.1 M | 69.2 M | 143 M | 153 M | 106 M | 188 M | 141 M | 139 M | 119 M | - | 136 M | 127 M | 116 M | - | 148 M | 114 M | 99.9 M | - | 106 M | 97.1 M | 80.5 M | - | 84.9 M | 87.1 M | 71.9 M | - | 77.4 M | 75.7 M | 71.2 M | - | 93 M | 65.3 M | 61.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 188 M | 20.3 M | 80.5 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Assembly Biosciences
ASMB
|
72.3 M | $ 30.08 | 5.69 % | $ 337 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 223.99 | 0.95 % | $ 5 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.41 | 2.55 % | $ 360 M |  Britain |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 158.23 | 0.83 % | $ 7.87 B | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Gilead Sciences
GILD
|
29.4 B | $ 138.83 | 1.18 % | $ 173 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
2.04 M | $ 0.58 | -3.33 % | $ 540 K |  Israel |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 7.75 | 2.24 % | $ 6.83 B |  Spain |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Compugen Ltd.
CGEN
|
6 M | $ 2.14 | 2.39 % | $ 200 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.45 | 1.47 % | $ 1.03 B | Canada |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
868 M | $ 28.15 | 1.55 % | $ 1.62 B | USA |
 |
Cara Therapeutics
CARA
|
21 M | - | -3.03 % | $ 260 M | USA |
 |
Heron Therapeutics
HRTX
|
155 M | $ 0.8 | 3.3 % | $ 133 M | USA |
 |
ChemoCentryx
CCXI
|
32.2 M | - | - | $ 3.74 B | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.57 | 2.96 % | $ 184 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
41 K | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
149 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Incyte Corporation
INCY
|
5.14 B | $ 92.2 | 1.56 % | $ 18 B | USA |
 |
InMed Pharmaceuticals
INM
|
4.14 M | $ 0.79 | -3.39 % | $ 1.93 M | Canada |
 |
INmune Bio
INMB
|
155 K | $ 1.17 | - | $ 21 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
18.1 M | $ 4.51 | 6.37 % | $ 748 M | Canada |